Suite 202, Newport Beach, CA 92660, our office serves patients from throughout Orange County including Irvine, Costa Mesa, Huntington Beach, Laguna Beach, Mission Viejo, and surrounding California communities
Double-checking takes 30 seconds and prevents weeks of suboptimal results or unnecessary side effects
2-Deoxy-D-glucose (2-DG), a glucose analog, enters cancer cells and competes with glucose-6-phosphate for HK2, whereby the phosphorylation of 2-DG to 2-DG-P blocks glycolysis and leads to ATP depletion and oxidative stress, resulting in anticancer effects [83]

GLP-1 Targeted Peptide Weight Loss Drugs Market, by BMI Category, 20242034 Table 9: Canada GLP-1 Targeted Peptide Weight Loss Drugs Market, by Segments, 20242034 Table 10: Mexico GLP-1 Targeted Peptide Weight Loss Drugs Market, by Segments, 20242034 Table 11: Germany GLP-1 Targeted Peptide Weight Loss Drugs Market, by Drug, 20242034 Table 12: Germany GLP-1 Targeted Peptide Weight Loss Drugs Market, by Route of Administration, 20242034 Table 13: Germany GLP-1 Targeted Peptide Weight Loss Drugs Market, by Distribution Channel, 20242034 Table 14: Germany GLP-1 Targeted Peptide Weight Loss Drugs Market, by Dosage Strength, 20242034 Table 15: Germany GLP-1 Targeted Peptide Weight Loss Drugs Market, by End User, 20242034 Table 16: Germany GLP-1 Targeted Peptide Weight Loss Drugs Market, by Therapy Line, 20242034 Table 17: Germany GLP-1 Targeted Peptide Weight Loss Drugs Market, by Patient Age Group, 20242034 Table 18: Germany GLP-1 Targeted Peptide Weight Loss Drugs Market, by BMI Category, 20242034 Table 19: France GLP-1 Targeted Peptide Weight Loss Drugs Market, by Segments, 20242034 Table 20: UK GLP-1 Targeted Peptide Weight Loss Drugs Market, by Segments, 20242034 Table 21: Italy GLP-1 Targeted Peptide Weight Loss Drugs Market, by Segments, 20242034 Table 22: Rest of Europe GLP-1 Targeted Peptide Weight Loss Drugs Market, by Segments, 20242034 Table 23: China GLP-1 Targeted Peptide Weight Loss Drugs Market, by Drug, 20242034 Table 24: China GLP-1 Targeted Peptide Weight Loss Drugs Market, by Route of Administration, 20242034 Table 25: China GLP-1 Targeted Peptide Weight Loss Drugs Market, by Distribution Channel, 20242034 Table 26: China GLP-1 Targeted Peptide Weight Loss Drugs Market, by Dosage Strength, 20242034 Table 27: China GLP-1 Targeted Peptide Weight Loss Drugs Market, by End User, 20242034 Table 28: China GLP-1 Targeted Peptide Weight Loss Drugs Market, by Therapy Line, 20242034 Table 29: China GLP-1 Targeted Peptide Weight Loss Drugs Market, by Patient Age Group, 20242034 Table 30: China GLP-1 Targeted Peptide Weight Loss Drugs Market, by BMI Category, 20242034 Table 31: Japan GLP-1 Targeted Peptide Weight Loss Drugs Market, by Segments, 20242034 Table 32: South Korea GLP-1 Targeted Peptide Weight Loss Drugs Market, by Segments, 20242034 Table 33: India GLP-1 Targeted Peptide Weight Loss Drugs Market, by Segments, 20242034 Table 34: Southeast Asia GLP-1 Targeted Peptide Weight Loss Drugs Market, by Segments, 20242034 Table 35: Rest of Asia Pacific GLP-1 Targeted Peptide Weight Loss Drugs Market, by Segments, 20242034 Table 36: Brazil GLP-1 Targeted Peptide Weight Loss Drugs Market, by Segments, 20242034 Table 37: Rest of Latin America GLP-1 Targeted Peptide Weight Loss Drugs Market, by Segments, 20242034 Table 38: GCC Countries GLP-1 Targeted Peptide Weight Loss Drugs Market, by Segments, 20242034 Table 39: Turkey GLP-1 Targeted Peptide Weight Loss Drugs Market, by Segments, 20242034 Table 40: Africa GLP-1 Targeted Peptide Weight Loss Drugs Market, by Segments, 20242034 Table 41: Rest of MEA GLP-1 Targeted Peptide Weight Loss Drugs Market, by Segments, 20242034 Figure 1: U.S
